17th Feb 2021 11:56
SkinBioTherapeutics PLC - AIM-listed life science company - Says its subsidiary AxisBiotix Ltd commences AxisBiotix-Ps food supplement consumer study. SkinBioTherapeutics, with its partner Winclove Probiotics BV, developed a blend of bacterial strains in the form of a food supplement. The food supplement blend has been named AxisBiotix-Ps, and enrolment for a "self-managed" consumer study of the supplement commenced in January. Following an extremely high level of demand for participation in the study, the capacity was increased from 200 to 265 participants with the additional 65 places focussing on non-psoriatic conditions to explore the possible impact of probiotics on other skin conditions. The study will be monitored through a bespoke mobile device app, allowing for the study to progress amid Covid-19 restrictions, the company notes.
Current stock price: 40.78 pence
Year-to-date change: up 74%
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Skinbiotherap.